EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals (Nasdaq: EYPT), a retinal disease therapeutics company, has granted inducement stock options to eight new employees outside of its 2023 Long-Term Incentive Plan. The grants, approved on September 15, 2025, include options to purchase up to 140,600 shares at an exercise price of $13.41 per share.
The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting monthly over three years, contingent on continued employment.
EyePoint Pharmaceuticals (Nasdaq: EYPT), una società di terapie per malattie della retina, ha concesso stock option di indigenza (inducement) a otto nuovi dipendenti al di fuori del suo Piano di Incentivazione a Lungo Termine 2023. Le assegnazioni, approvate il 15 settembre 2025, includono opzioni per l'acquisto di fino a 140.600 azioni a un prezzo di esercizio di 13,41 USD per azione.
Le opzioni hanno una durata di dieci anni e seguono un periodo di maturazione di quattro anni, con il 25% che matura dopo il primo anno e il resto che matura mensilmente nel corso dei tre anni successivi, soggetto al mantenimento del rapporto di lavoro.
EyePoint Pharmaceuticals (Nasdaq: EYPT), una empresa de terapias para enfermedades de la retina, ha otorgado opciones de compra de acciones por incentivo a ocho nuevos empleados fuera de su Plan de Incentivos a Largo Plazo 2023. Las adjudicaciones, aprobadas el 15 de septiembre de 2025, incluyen opciones para comprar hasta 140.600 acciones a un precio de ejercicio de 13,41 USD por acción.
Las opciones tienen un plazo de diez años y siguen un período de consolidación de cuatro años, con un 25% de consolidación tras el primer año y el resto consolidándose mensualmente durante los tres años siguientes, sujeto a la continuidad del empleo.
EyePoint Pharmaceuticals (Nasdaq: EYPT), 망막 질환 치료제를 개발하는 회사는 2023년 장기 인센티브 플랜 외에 새로운 직원 8명에게 유도 보상 주식 옵션을 부여했습니다. 승인일은 2025년 9월 15일이며, 행사가격은 주당 13.41달러로 최대 140,600주의 주식매수옵션이 포함되어 있습니다.
옵션의 만료 기간은 10년이고, 4년 vesting 일정을 따르며, 1년 차에 25%가 vesting되고 나머지는 3년간 매월 vesting됩니다. 고용 지속 여부에 따라 달라질 수 있습니다.
EyePoint Pharmaceuticals (Nasdaq: EYPT), une société dédiée aux thérapies des maladies rétiniennes, a accordé des options d’achat d’actions d’induction à huit nouveaux employés en dehors de son Plan d’Incitation à Long Terme 2023. Les attributions, approuvées le 15 septembre 2025, comprennent des options d’achat jusqu’à 140 600 actions à un prix d’exercice de 13,41 USD par action.
Les options ont une durée de dix ans et suivent un calendrier de vesting de quatre ans, avec 25% qui vest après la première année et le reste qui vest mensuellement sur les trois années suivantes, sous réserve du maintien de l’emploi.
EyePoint Pharmaceuticals (Nasdaq: EYPT), ein Unternehmen für Retinaderkrankungen, hat acht neue Mitarbeiter außerhalb des Long-Term Incentive Plans 2023 mit Inducement-Stocksoptionen bedacht. Die Zuteilungen, genehmigt am 15. September 2025, umfassen Optionen zum Kauf von bis zu 140.600 Aktien zu einem Ausübungspreis von 13,41 USD pro Aktie.
Die Optionen haben eine Laufzeit von zehn Jahren und folgen einem Vesting-Plan von vier Jahren, bei dem 25% nach dem ersten Jahr vesten und der Rest über drei Jahre hinweg monatlich vestet, vorbehaltlich der fortgesetzten Beschäftigung.
EyePoint Pharmaceuticals (Nasdaq: EYPT)، شركة أدوية أمراض الشبكية، قد منحت خيارات أسهم تحفيزية لـثمانية موظفين جدد خارج خطة الحوافز طويلة الأجل لعام 2023. تشمل المنح، التي تمت الموافقة عليها في 15 سبتمبر 2025، خيارات شراء حتى 140,600 سهم بسعر تنفيذ قدره 13.41 دولار للسهم.
تملك الخيارات فترة سريان عشر سنوات وتتبع جدول vesting لمدة أربعة أعوام، مع 25% يتكشف بعد السنة الأولى وباقي الفترة يتكشف شهرياً على مدى ثلاث سنوات مقبلة، رهناً باستمرار التوظيف.
EyePoint Pharmaceuticals (纳斯达克代码:EYPT)，一家视网膜疾病治疗公司，已向8名新员工授予诱导性股票期权，超出其2023年度长期激励计划。该等授予经在2025年9月15日批准，其中包括在每股行使价为13.41美元的前提下购买最多140,600股的期权。
这些期权的期限为十年，并遵循一个为期四年的归属计划，其中在第一年结束时有25%归属于（vest），其余部分在接下来的三年中按月归属，前提是雇佣关系持续。
- None.
- None.
WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 140,600 shares of EyePoint common stock to eight new employees. The stock options were granted on September 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data to date, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data anticipated in 2026. DURAVYU also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD is the leading cause of vision loss among people 50 years of age and older in the United States.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
For EyePoint:
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
What stock options did EyePoint Pharmaceuticals (EYPT) grant to new employees in September 2025?
What is the vesting schedule for EYPT's September 2025 employee stock options?
What was the exercise price for EyePoint's September 2025 inducement grants?
How many new employees received stock options from EyePoint Pharmaceuticals in September 2025?
